Boston Scientific beats by $0.15, beats on revs; guides Q1 EPS above consensus, revs in-line (BSX) 12.85 +0.48 : Reports Q4 (Dec) earnings of $0.24 per share, excluding charges and amortization expense, $0.15 better than the First Call consensus of $0.09; revenues rose 4.2% year/year to $2.15 bln vs the $2.13 bln consensus.
Co issues mixed guidance for Q1, sees EPS of 0.15-0.20, excluding charges and amortization expense, vs. $0.12 consensus; sees Q1 revs of 1.96-2.08 bln vs. $2.09 bln consensus.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment